Next Article in Journal
Uterine Rupture in the Second Trimester of Pregnancy as an Iatrogenic Complication of Laparoscopic Myomectomy
Previous Article in Journal
The Impact of Complex Cardiac Rehabilitation on Manifestation of Risk Factors in Patients with Coronary Heart Disease
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Non–Small Cell Lung Cancer

1
Department of Pulmonology and Immunology, Medical Academy, Lithuanian University of Health Sciences
2
Department of Pathological Anatomy, Medical Academy, Lithuanian University of Health Sciences
3
Department of Laboratory Medicine, Medical Academy, Lithuanian University of Health Sciences, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2012, 48(4), 25; https://doi.org/10.3390/medicina48040025
Received: 11 February 2012 / Accepted: 24 April 2012 / Published: 29 April 2012
Objective. The aim of this study was to examine the prevalence of epidermal growth factor receptor (EGFR) gene mutations among patients with advanced nonsquamous non–small cell lung cancer (NSCLC) treated in our institution and to evaluate the associations between EGFR mutations and clinicopathological characteristics.
Materials and Methods
. A total of 103 patients with NSCLC were examined from April 2010 to September 2011. The patients were screened for EGFR mutations in exons 19 and 21 using sequence analysis.
Results
. EGFR mutations were detected in 10 patients (9.71%): 23.1% of women and 5.2% of men (P<0.05), 31.8% of never-smokers and 4.7% of smokers (P<0.05), and 12.3% of patients with adenocarcinomas and 6.25% of patients with large cell carcinomas (P>0.05). Eight mutations (80.0%) were found in exon 21: 7 patients had the L858R mutation and 1 patient had the L861G mutation. Two mutations (20.0%) were found in exon 19: 1 patient had the L747-A748 deletion and 1 patient had the L747-A750insE deletion. The overall response rate was significantly greater in the EGFR mutation-positive group than in the EGFR mutation-negative or control groups (P<0.05). The median progression-free survival in the EGFR mutation-negative group and the control group that received systemic standard chemotherapy was 5.6 months (95% CI, 4.3 to 7.0) and 5.3 months (95% CI, 4.9 to 5.7), respectively, but it was not achieved in the EGFR mutation-positive group that received EGFR tyrosine kinase inhibitors (P<0.05).
Conclusions. The frequency of EGFR mutations in our patients with nonsquamous NSCLC was found to be similar to that reported in Europe. EGFR mutations were more frequent in women and never-smokers
Keywords: non–small cell lung cancer; EGFR mutations; tyrosine kinase inhibitor non–small cell lung cancer; EGFR mutations; tyrosine kinase inhibitor
MDPI and ACS Style

Vagulienė, N.; Žemaitis, M.; Šarauskas, V.; Vitkauskienė, A.; Miliauskas, S. The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Non–Small Cell Lung Cancer. Medicina 2012, 48, 25.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop